S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.48
$1.63
50-Day Range
$1.48
$1.98
52-Week Range
$0.82
$3.88
Volume
3.91 million shs
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.91

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
232.0% Upside
$4.91 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.68) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

184th out of 969 stocks

Biological Products, Except Diagnostic Industry

23rd out of 161 stocks


TCRR stock logo

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.


TCRR Stock News Headlines

DICE Therapeutics Inc.
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
4 Analysts Have This to Say About TCR2 Therapeutics
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
Adaptimmune To Combine With TCR² In All-stock Deal - Quick Facts
TCRR.C - | Stock Price & Latest News | Reuters
See More Headlines
Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Company Calendar

Last Earnings
11/10/2021
Today
9/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.91
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$1.68
Forecasted Upside/Downside
+232.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-151,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.58 per share

Miscellaneous

Free Float
29,443,000
Market Cap
$58.10 million
Optionable
Not Optionable
Beta
1.95
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Garry E. Menzel
    President, Chief Executive Officer & Director
  • Peter Olagunju
    Chief Operating Officer
  • Eric M. Sullivan
    Chief Financial Officer
  • Alfonso Quintás-Cardama
    Chief Medical Officer
  • Praveen Malhotra
    Vice President-Information Technology













TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.
View TCRR analyst ratings
or view top-rated stocks.

What is TCR2 Therapeutics' stock price forecast for 2023?

7 Wall Street analysts have issued twelve-month target prices for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they predict the company's stock price to reach $4.91 in the next year. This suggests a possible upside of 232.0% from the stock's current price.
View analysts price targets for TCRR
or view top-rated stocks among Wall Street analysts.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include Alfonso Quintas Cardama, Garry E Menzel, Kevin C Tang, Mayur Ian Somaiya, Mpm Asset Management Llc and Robert Hofmeister.
View institutional ownership trends
.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $1.48.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $58.10 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

The company employs 137 workers across the globe.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -